Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Disposable Perfusion Phantom for Accurate DCE-MRI Measurement of Pancreatic Cancer Therapy Response

Pancreatic

This trial tests the use of a disposable perfusion phantom (P4) to decrease errors in calculating the blood flow of a tissue with DCE-MRI. DCE-MRI is used calculate blood flow of various tissues including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor has typically low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy may result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, DCE-MRI may be used to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and may help doctors decide whether to continue the therapy or try a different one. Unfortunately, the measurement of blood flow using DCE-MRI is not accurate. The use of an artificial tissue, named "phantom" or P4, together with a patient may help to reduce errors in DCE-MRI because errors will affect the images of both the patient and the phantom. Because it is known how the blood flow of the phantom appears when no errors are present, the phantom may be used to detect what kinds of errors are present in the image, how many errors are present in the image, and how to remove errors from the image.

Disease Sites: Pancreatic

Phase: N/A

Investigator: Xu, Junzhong

NCTID: NCT04588025

Protocol No: VICCGI2099

A Phase 3 Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator's Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma

Head/Neck

Disease Sites: Head/Neck

Phase: III

Investigator: Choe, Jennifer

NCTID: NCT06496178

Protocol No: VICC-DTHAN23576

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Multiple Cancer Types

Disease Sites: Neuroblastoma (Pediatrics), Pediatric Solid Tumors

Phase: N/A

Investigator: Kitko, Carrie

NCTID: NCT01590680

Protocol No: VICCPED1249

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum Based Chemotherapy

Multiple Cancer Types

Disease Sites: Gynecologic, Ovarian

Phase: III

Investigator: Crispens, Marta

NCTID: NCT06580314

Protocol No: NRGGYNGY036

Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Patients with Multiple Myeloma

Multiple Myeloma

Disease Sites: Multiple Myeloma

Phase: N/A

Investigator: Oluwole, Olalekan

NCTID: NCT05346835

Protocol No: VICC-XDCTT24033

Randomized Phase III Trial of Neoadjuvant Immunotherapy with Response-Adapted Treatment versus Standard-of-Care Treatment for Resectable Stage III/IV Cutaneous Squamous Cell Carcinoma

Head/Neck

Disease Sites: Head/Neck

Phase: III

Investigator: Choe, Jennifer

NCTID: NCT06568172

Protocol No: NRGHNHN014

A First-In-Human, Phase 1, Dose-Escalation Study of SGR-3515 In Participants with Advanced Solid Tumors

Disease Sites: Not Available

Phase: I

Investigator: Gibson, Mike

NCTID: NCT06463340

Protocol No: VICC-DTPHI24100

Clinical Trial Flowcharts
for Referring Physicians

Clinical Trial Flowcharts
for VICC Staff (VUNetID required)

Clinical Trials Search CTA Inline Referral Form